Clinical Trials · NCT04569591

DDAVP for Pituitary Adenoma

Phase
N/A
Recruitment status
Recruiting
Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Enrollment
22
Start date
Mar 2026
Locations
1 site, United States
Primary endpoint
The primary outcome measure will be defined as whether or not DDAVP-stimulated PET imaging demonstrates tumor in MRI-negative cases.
View Desmopressin compound reference